Skip to content

8-KAccepted Nov 16, 7:03 AM ET

InMed Pharmaceuticals: completes acquisition of Mentari

MTRIInMed Pharmaceuticals Inc.

Accepted (ET)

7:03 AM

Nov 16, 2026

Filed

Nov 16, 2026

Documents

13

Size

750.6 KB

Summary

InMed Pharmaceuticals: completes acquisition of Mentari

Updated

What happened

  • InMed Pharmaceuticals filed an 8-K reporting completion of the acquisition of Mentari (Item 2.01).
  • The filing attached Mentari’s unaudited condensed consolidated financial statements as of Sep 30, 2026 and for the three and nine months ended Sep 30, 2026, and Mentari’s management’s discussion and analysis for those periods.

Key details

  • Mentari’s unaudited financial statements are included as Exhibit 99.1 and its MD&A is included as Exhibit 99.2.
  • The Proxy Statement/Prospectus for the merger was filed on Form S-4 (File No. 333-297234), most recently amended on Sep 29, 2026 and declared effective on Oct 1, 2026.
  • The filing references risk factors for Mentari beginning on page 84 of the Proxy Statement/Prospectus, risks related to the redomestication beginning on page 122, and risks related to the combined company beginning on page 124.
  • The 8-K also reports information regarding results of operations and financial condition (Item 2.02).

Why it may matter

  • The filing reports completion of the acquisition (Item 2.01), provides information on results of operations and financial condition (Item 2.02), and includes Mentari’s unaudited financial statements and MD&A (Item 9.01).
  • A filing does not show why the insider traded or why the company acted.

AI-written summary · check the filing